Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: A double-blind, placebo-controlled, randomized trial

International Clinical Psychopharmacology

Volumn 31, Issue 1, 2016, Pages 20-26

  Emadi Kouchak, Hamid ^a   Mohammadinejad, Payam ^b   Asadollahi Amin, Ali ^a   Rasoulinejad, Mehrnaz ^a   Zeinoddini, Atefeh ^b   Yalda, Alireza ^a   Akhondzadeh, Shahin ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

clinical trial; depression; depressive disorder; double blind method; HIV; minocycline

Indexed keywords

MINOCYCLINE; PLACEBO; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT DURATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; COMPLICATION; MIDDLE AGED; PSYCHOLOGY; STATISTICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MINOCYCLINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84951570122     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000098     Document Type: Article

References (48)

1. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. (2012). Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebocontrolled study. J Affect Disord 141: 308-314
2. Abbasi SH, Mohammadinejad P, Shahmansouri N, Salehiomran A, Beglar AA, Zeinoddini A, et al. (2015). Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. J Affect Disord 183: 149-155
3. Adams JL, Gaynes BN, McGuinness T, Modi R, Willig J, Pence BW. (2012). Treating depression within the HIV medical home: a guided algorithm for antidepressant management by HIV clinicians. AIDS Patient Care STDS 26: 647-654
4. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, et al. (2009). Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26: 607-611
5. Alciati A, Gallo L, Monforte AD, Brambilla F, Mellado C. (2007). Major depressionrelated immunological changes and combination antiretroviral therapy in HIVseropositive patients. Hum Psychopharmacol 22: 33-40
6. Carrico AW, Antoni MH, Duran RE, Ironson G, Penedo F, Fletcher MA, et al. (2006). Reductions in depressed mood and denial coping during cognitive behavioral stress management with HIV-positive gay men treated with HAART. Ann Behav Med 31: 155-164
7. Carrico AW, Johnson MO, Morin SF, Remien RH, Charlebois ED, Steward WT, Chesney MA, NIMH Healthy Living Project Team. (2007). Correlates of suicidal ideation among HIV-positive persons. AIDS 21: 1199-1203
8. Ciesla JA, Roberts JE. (2001). Meta-Analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 158: 725-730
9. Clifford DB. (2002). AIDS dementia. Med Clin North Am 86: 537-550
10. Cysique LA, Deutsch R, Atkinson JH, Young C, Marcotte TD, Dawson L, et al. (2007). Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc 13: 1-11
11. Dean OM, Maes M, Ashton M, Berk L, Kanchanatawan B, Sughondhabirom A, et al. (2014). Protocol and rationale-The efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial. Clin Psychopharmacol Neurosci 12: 180-188
12. DeLorenze GN, Satre DD, Quesenberry CP, Tsai AL, Weisner CM. (2010). Mortality after diagnosis of psychiatric disorders and co-occurring substance use disorders among HIV-infected patients. AIDS Patient Care STDS 24: 705-712
13. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, et al. (2001). Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinsons disease. Proc Natl Acad Sci USA 98: 14669-14674
14. Dube B, Benton T, Cruess DG, Evans DL. (2005). Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci 30: 237-246
15. Ferrando SJ, Freyberg Z. (2008). Treatment of depression in HIV positive individuals: a critical review. Int Rev Psychiatry 20: 61-71
16. Ferrarese C, Aliprandi A, Tremolizzo L, Stanzani L, De Micheli A, Dolara A, Frattola L. (2001). Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology 57: 671-675
17. Fujita Y, Ishima T, Kunitachi S, Hagiwara H, Zhang L, Iyo M, Hashimoto K. (2008). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry 32: 336-339
18. Gibbie T, Hay M, Hutchison CW, Mijch A. (2007). Depression, social support and adherence to highly active antiretroviral therapy in people living with HIV/AIDS. Sex Health 4: 227-232
19. Hamilton M. (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56
20. Himelhoch S, Brown CH, Walkup J, Chander G, Korthius PT, Afful J, Gebo KA. (2009). HIV patients with psychiatric disorders are less likely to discontinue HAART. AIDS 23: 1735-1742
21. Jafari S, Ashrafizadeh SG, Zeinoddini A, Rasoulinejad M, Entezari P, Seddighi S, Akhondzadeh S. (2015). Celecoxib for the treatment of mild-To-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial. J Clin Pharm Ther 40: 441-446
22. Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, et al. (2014). Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res 215: 540-546
23. Kim HS, Suh YH. (2009). Minocycline and neurodegenerative diseases. Behav Brain Res 196: 168-179
24. Kiselycznyk C, Jury NJ, Halladay LR, Nakazawa K, Mishina M, Sprengel R, et al. (2015). NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism. Behav Brain Res 287: 89-95
25. Kremlev SG, Roberts RL, Palmer C. (2004). Differential expression of chemokines and chemokine receptors during microglial activation and inhibition. J Neuroimmunol 149: 1-9
26. Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, et al. (2003). Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 20: 1017-1027
27. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. (2008). Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 31: 287-292
28. Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, et al. (2012). Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 37: 222-226
29. Mohammadinejad P, Arya P, Esfandbod M, Kaviani A, Najafi M, Kashani L, et al. (2015). Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double-blind, placebo-controlled, randomized trial. Ann Pharmacother 49: 953-961
30. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. (2008). Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 32: 380-386
31. Mulhaupt F, Matter CM, Kwak BR, Pelli G, Veillard NR, Burger F, et al. (2003). Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 59: 755-766
32. Poudel-Tandukar K, Bertone-Johnson ER, Palmer PH, Poudel KC. (2014). Creactive protein and depression in persons with human immunodeficiency virus infection: the Positive Living with HIV (POLH) Study. Brain Behav Immun 42: 89-95
33. Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM, GLYX-13 Clinical Study Group. (2015). Randomized proof of concept trial of GLYX-13, an N-methyl-D-Aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract 21: 140-149
34. Rabkin JG, Rabkin R, Harrison W, Wagner G. (1994). Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 151: 516-523
35. Rabkin JG, Wagner GJ, Rabkin R. (1999). Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 156: 101-107
36. Robinson MJ, Qaqish RB. (2002). Practical psychopharmacology in HIV-1 and acquired immunodeficiency syndrome. Psychiatr Clin North Am 25: 149-175
37. Sacktor N, Miyahara S, Deng L, Evans S, Schifitto G, Cohen BA, et al. (2011). Minocycline treatment for HIV-Associated cognitive impairment: results from a randomized trial. Neurology 77: 1135-1142
38. Sacktor N, Miyahara S, Evans S, Schifitto G, Cohen B, Haughey N, et al. (2014). Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol 20: 620-626
39. Sledjeski EM, Delahanty DL, Bogart LM. (2005). Incidence and impact of posttraumatic stress disorder and comorbid depression on adherence to HAART and CD4 + counts in people living with HIV. AIDS Patient Care STDS 19: 728-736
40. Soczynska JK, Mansur RB, Brietzke E, Swardfager W, Kennedy SH, Woldeyohannes HO, et al. (2012). Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res 235: 302-317
41. Suk K. (2004). Minocycline suppresses hypoxic activation of rodent microglia in culture. Neurosci Lett 366: 167-171
42. Watkins CC, Treisman GJ. (2012). Neuropsychiatric complications of aging with HIV. J Neurovirol 18: 277-290
43. Watkins CC, Treisman GJ. (2015). Cognitive impairment in patients with AIDS-prevalence and severity. HIV AIDS (Auckl) 7: 35-47
44. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. (1999). A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96: 13496-13500
45. Zeinoddini A, Ahadi M, Farokhnia M, Rezaei F, Tabrizi M, Akhondzadeh S. (2014). L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial. J Psychiatr Res 59: 125-131
46. Zeinoddini A, Sorayani M, Hassanzadeh E, Arbabi M, Farokhnia M, Salimi S, et al. (2015). Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depress Anxiety 32: 167-173
47. Zhang L, Shirayama Y, Iyo M, Hashimoto K. (2007). Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 32: 2004-2010
48. Zhang W, Narayanan M, Friedlander RM. (2003). Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 53: 267-270